A Phase 1 interventional study of STEM-OA in Osteoarthritis, Knee, sponsored by StemMedical A/S. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-03-29.
Sponsored by StemMedical A/S · Phase 1, Interventional, and Treatment
A phase 1 exploratory clinical study to investigate safety, tolerance and efficacy of a single intra-articular injection of autoSTEM-OA or alloSTEM-OA in participants with mild to moderate knee osteoarthritis
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's planned enrollment of 20 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →This is the only study on the registry with StemMedical A/S as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
400x10\^6 autologous MSC(AT)s in autologous fat
Biological: STEM-OA
400x10\^6 allogeneic MSC(AT)s in autologous fat
Biological: STEM-OA
800x10\^6 autologous MSC(AT)s in autologous fat
Biological: STEM-OA
800x10\^6 allogeneic MSC(AT)s in autologous fat
Biological: STEM-OA
1600x10\^6 autologous MSC(AT)s in autologous fat
Biological: STEM-OA
1600x10\^6 allogeneic MSC(AT)s in autologous fat
Biological: STEM-OA
Combination of autologous or allogeneic MSC(AT)s and fat
STEM-OA safety
Number of treatment emergent adverse events (TEAEs)
Time frame: 13 weeks
Knee pain
Change in KOOS 'pain' score
Time frame: 13 weks
Number of treatment responders
Number of treatment responders according to the OMERACT-OARSI criteria
Time frame: 13 weks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.